2024年国庆期间,港股市场迎来 医药行业 标志性事件——嘉和生物与亿腾医药宣布合并计划,成为港交所18A规则下首例反向收购案例。此次交易完成后对于亿腾医药这家曾经中国CSO的龙头后转型为 综合 性pharma的企业来说,不仅能成功完成上市,更能携手嘉和再次升级Biopharma,引发了 资本市场 的高度关注。反向收购创新路径,亿腾上市迈出关键一步根据协议,合并后新公司中,原亿腾医药股东将持股...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.